Xenon Pharmaceuticals Inc.
XENE
Rang în acțiuni
#4666
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Preț acțiune
$33.60
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$3.25B
Schimbare (1 zi)
-2.13%
Schimbare (1 an)
-19.29%
Țară
CA
Tranzacționează Xenon Pharmaceuticals Inc. (XENE)
Categorie
Healthcare
Marja operațională pentru Xenon Pharmaceuticals Inc. (XENE)
Marja operațională la October 2026 TTM: 0.00%
Conform celor mai recente rapoarte financiare și prețului acțiunilor Xenon Pharmaceuticals Inc., marja operațională curentă (TTM) este 0.00%. La finalul anului 2023, compania avea o marjă operațională de 0.00%.
Istoricul marjei operaționale pentru Xenon Pharmaceuticals Inc. din 2011 până în 2026
Marja operațională la sfârșitul fiecărui an
| An | Marja Operațională | Schimbă |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -1,368.91% | 219.50% |
| 2021 | -428.45% | 340.29% |
| 2020 | -97.31% | -84.48% |
| 2019 | -627.02% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2017 | -10,474.28% | 660.97% |
| 2016 | -1,376.43% | 2,190.23% |
| 2015 | -60.10% | -253.51% |
| 2014 | 39.15% | 10.28% |
| 2013 | 35.50% | -261.07% |
| 2012 | -22.04% | -87.41% |
| 2011 | -175.11% | 0.00% |
Marja operațională pentru companii similare sau concurente
| Companie | Marja Operațională | Diferență în marja operațională | Țara |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | - |
NL
|
Ce este marja operațională a unei companii?
Marja operațională este un indicator esențial pentru evaluarea profitabilității unei companii. Marjele operaționale mai mari sunt de obicei mai bune, deoarece arată că o companie poate vinde produsele sau serviciile sale la prețuri mult mai mari decât costurile de producție. Marja operațională se calculează împărțind profitul companiei la venitul său.